“Re-educating” tumor-associated macrophages by targeting NF-κB
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The nuclear factor κB (NF-κB) signaling pathway is important in cancer-related inflammation and malignant progression. Here, we describe a new role for NF-κB in cancer in maintaining the immunosuppressive phenotype of tumor-associated macrophages (TAMs). We show that macrophages are polarized via interleukin (IL)-1R and MyD88 to an immunosuppressive “alternative” phenotype that requires IκB kinase β–mediated NF-κB activation. When NF-κB signaling is inhibited specifically in TAMs, they become cytotoxic to tumor cells and switch to a “classically” activated phenotype; IL-12high, major histocompatibility complex IIhigh, but IL-10low and arginase-1low. Targeting NF-κB signaling in TAMs also promotes regression of advanced tumors in vivo by induction of macrophage tumoricidal activity and activation of antitumor activity through IL-12–dependent NK cell recruitment. We provide a rationale for manipulating the phenotype of the abundant macrophage population already located within the tumor microenvironment; the potential to “re-educate” the tumor-promoting macrophage population may prove an effective and novel therapeutic approach for cancer that complements existing therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. IKKβ inhibition increases macrophage tumoricidal activity. (A) WT, MyD88−/−, TLR-2−/−, and TLR-4−/− or mock, IKKβDN or IKKβf/f, and IKKβΔ BMDMs were co-cultured with ID8-Luc in a modified Boyden chamber without direct cell–cell contact for 72 h. In addition, CD11b+-selected TAMs from the ascites of ID8 tumor–bearing mice were mock (TAMmock) or IKKβDN infected (TAMDN). Invasion of ID8-Luc cells was assessed by luciferase activity in the lower part of the chamber. Macrophages deleted in MyD88, IL-1R, or IKKβ significantly reduce ID8-Luc invasion (P < 0.01; t test with Welch's correction). Data are represented as mean ± SEM of n = 6. Representative data are shown from at least three independent experiments. (B) ID8 cells were co-cultured with IKKβ-targeted BMDMs or TAMs and respective control cells. Fluorescence caspase 3/7 activity was assessed after 0, 3, and 6 h. Co-culture with IKKβDN and IKKβΔ BMDMs or TAMs expressing IKKβDN (TAMDN) significantly increases caspase 3/7 activity in ID8 cells (P < 0.01; t test with Welch's correction). Data are represented as mean ± SD of n = 6. Representative data are shown from at least three independent experiments. (C) [111In]oxine release assay after a 24-h co-culture of 111In-labeled ID8 cells with mock, IKKβDN, TAMDN or IKKβf/f, and IKKβΔ macrophages. 111In-release in cell-free culture supernatants was measured after 24 h with a scintillation counter. IKKβ-targeted macrophages promote increased cytotoxicity. Data are represented as mean of n = 3. Representative data are shown from at least three independent experiments.](https://figures.cochat.ai/paper-figures/741fab83e5184295af0f590a594611ed/re-educating-tumor-associated-macrophages-by-targeting-nf-b-figure-1.jpg)
![Figure 2. IKKβ maintains the alternative phenotype of tumor-polarized macrophages. WT, mock, IKKβDN or IKKβf/f, and IKKβΔ BMDMs were co-cultured with ID8 cells for 24 h. Supernatant was collected after 24 h and analyzed for IL-10, IL-12p70, TNF-α, and NO production by ELISA. (A) Co-cultured WT macrophages express an immunosuppressive IL-10high IL-12p70low TNF-αhigh profile. However, supernatant from co-cultured IKKβ-deleted macrophages show a significant decrease in IL-10 and TNF-α (P < 0.01; t test with Welch's correction) but increase in IL-12p70 (P < 0.01; t test with Welch's correction). Data are represented as mean ± SD of n = 3. Representative data are shown from at least three independent experiments. (B) In parallel, total RNA was isolated for real-time PCR analysis of IL-12p40 and arginase-1 in co-cultured macrophages. Targeting IKKβ in macrophages switches their phenotype to an IL-12high arginase-1low NOS2high profile, consistent with an M1 phenotype. In_addition, IKKβ-targeted macrophages secrete significantly higher levels of NO, measured as nitrite by Griess assay (P < 0.01; Mann-Whitney test). Data are represented as mean ± SD of n = 3. Representative data are shown from at least four independent experiments. (C) Macrophages were co-cultured with ID8 cells, and protein extracts were prepared at the indicated time points for biochemical analysis. Expression of NF-κB p65, serine 536 phosphorylation of p65, IKKβ, Stat1, tyrosine 701 phosphorylation of Stat1 (Tyr701), and NOS2 was measured by immunoblot analysis of cell lysates using β-actin as a loading control. Representative data are shown from at least three independent experiments. (D) [111In]oxine release assay after co-culture of ID8 ovarian cancer cells with IKKβDN or IKKβΔ BMDMs. IKKβ-targeted macrophages promote increased cytotoxicity that was reversed by the addition of the selective NOS2 inhibitor 1400W. Data are represented as mean of n = 3. Representative data are shown from at least three independent experiments.](https://figures.cochat.ai/paper-figures/2ca0616e0f4f417d8bd81ac7dc101f6c/re-educating-tumor-associated-macrophages-by-targeting-nf-b-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages
Xie, Q.-W., Cho, H. J., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T., & Nathan, C. (1992) · Science · doi:10.1126/science.1373522 · Cited by 1,886
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Self-citationColony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Cited by
Items 301–400 of 802
Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy
Yang, P., Yu, M., Hou, Y., Chang, C., Lin, S.-C., Kuo, I., Su, P.-C., Cheng, H., Su, W., Shan, Y.-S., et al. (2021) · Theranostics · doi:10.7150/thno.65522 · Cited by 75
“a promoting role of NF-κB in maintaining the phenotype of M2-TAMs [29, 30].”
BackgroundTargeting complement-mediated immunoregulation for cancer immunotherapy
Kolev, M. V., & Markiewski, M. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.003 · Cited by 72
Myeloid IKKβ Promotes Antitumor Immunity by Modulating CCL11 and the Innate Immune Response
Yang, J., Hawkins, O. E., Barham, W. J., Gilchuk, P., Boothby, M. R., Ayers, G. D., Joyce, S., Karin, M., Yull, F. E., & Richmond, A. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1091 · Cited by 73
Breast tumor stroma: A driving force in the development of resistance to therapies
Majidinia, M., & Yousefi, B. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12893 · Cited by 68
Luchini, C., Cros, J. F., Pea, A., Pilati, C., Veronese, N., Rusev, B. C., Capelli, P., Mafficini, A., Nottegar, A., Brosens, L. A. A., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.07.006 · Cited by 89
A Role for T-Lymphocytes in Human Breast Cancer and in Canine Mammary Tumors
Carvalho, M. I., Pires, I. C. R., Prada, J., & QUEIROGA, F. L. (2014) · BioMed Research International · doi:10.1155/2014/130894 · Cited by 81
“Cancer is a progressive process that arises from a welldefined step where somatic cells acquire activating (oncogenes) or deactivating (tumor suppressor genes) mutations [4, 5].”
Dissection of platelet and myeloid cell defects by conditional targeting of the β3‐integrin subunit
Morgan, E. A., Schneider, J. G., Baroni, T. E., Uluçkan, Ö., Heller, E., Hurchla, M. A., Deng, H., Floyd, D. H., Berdy, A., Prior, J. L., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-138420 · Cited by 77
“Macrophages can exert tumoricidal activity or support tumor progression and metastasis (41, 42).”
BackgroundGenetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy
Moyes, K. W., Lieberman, N. A. P., Kreuser, S. A., Chinn, H. K., Winter, C., Deutsch, G. H., Hoglund, V. J., Watson, R., & Crane, C. A. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.060 · Cited by 71
Roy, A., Singh, M. S., Upadhyay, P. K., & Bhaskar, S. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.045 · Cited by 69
Macrophage Polarization and Its Role in Cancer
Smith, E. W. C. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000338 · Cited by 92
“In fact, inhibition of NF-κB in TAMs promotes classical activation [46].”
BackgroundDugo, L., Belluomo, M. G., Fanali, C., Russo, M., Cacciola, F., Maccarrone, M., & Sardanelli, A. M. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6293740 · Cited by 68
Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer
Akkari, L., Gocheva, V., Quick, M. L., Kester, J. C., Spencer, A. K., Garfall, A. L., Bowman, R. L., & Joyce, J. A. (2016) · Genes & Development · doi:10.1101/gad.270439.115 · Cited by 72
“NFκB activity in TAMs has been shown to regulate and maintain macrophage activation and modulate tumor-promoting phenotypes in response to diverse environmental cues, including stress signals, inflammatory cytokines, and infection (Karin and Greten 2005; Hagemann et al. 2008).”
BackgroundDrug delivery strategy in hepatocellular carcinoma therapy
Yang, S., Cai, C., Wang, H., Ma, X., Shao, A., Sheng, J., & Yu, C. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00796-x · Cited by 70
The role of inflammation in progression of breast cancer: Friend or foe? (Review)
Allen, M. D., & Jones, J. L. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3075 · Cited by 74
Chakraborty, S., Zawieja, S. D., Wang, W., Lee, Y., Wang, Y. J., von der Weid, P., Zawieja, D. C., & Muthuchamy, M. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00467.2015 · Cited by 74
NF-κB signaling as a driver of ageing
Osorio, F. G., Soria‐Valles, C., Santiago‐Fernández, O., Freije, J. M. P., & López-Otín, C. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.04.003 · Cited by 75
Pai, P., & Sukumar, S. V. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188450 · Cited by 71
Song, H., Jung, J. I., Cho, H., Her, S., Kwon, S., Yu, R., Kang, Y., Lee, K. W., & Park, J. H. Y. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.07.005 · Cited by 70
“NFκB has also been implicated in driving the M2 polarization of TAMs [34].”
BackgroundSuh, D. H., Kim, H. S., Kim, B., & Song, Y. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.011 · Cited by 69
Sun, T., Yang, Y., Luo, X., Cheng, Y. Z., Zhang, M., Wang, K., & Ge, C. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504014x13890370410285 · Cited by 72
Circulating tumor cell interactions with macrophages: implications for biology and treatment
Hamilton, G., & Rath, B. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.07.04 · Cited by 67
Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma
Pires‐Afonso, Y., Niclou, S. P., & Michelucci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030689 · Cited by 68
“In cancer, targeting NFκB prompts TAMs towards a more cytotoxic anti-tumorigenic phenotype with a more activated state characterized by higher IL12 and MHC-II expression together with reduced levels of IL10 and ARG1 [38].”
BackgroundInnate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy
Cortés‐Selva, D., Dasgupta, B., Singh, S., & Grewal, I. S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.004 · Cited by 66
Lin, L., Chen, S., Wang, H., Gao, B., Kallakury, B., Bhuvaneshwar, K., Cahn, K., Gusev, Y., Wang, X., Wu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.49819 · Cited by 64
“They serve as a critical link between inflammation and cancer formation, and have been shown to promote cancer progression via regulation of apoptosis, tumor angiogenesis, tumor invasion, and immune evasion [15-19].”
BackgroundHe, X.-Y., Xiang, C., Zhang, C.-X., Xie, Y.-Y., Chen, L., Zhang, G.-X., Lu, Y., & Liu, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.045 · Cited by 62
Activated macrophages in the tumour microenvironment—dancing to the tune of TLR and NF‐κB
Hallam, S. L., Escorcio‐Correia, M., Soper, R., Schultheiss, A., & Hagemann, T. (2009) · The Journal of Pathology · doi:10.1002/path.2602 · Cited by 73
“Both studies showed that IKKβ and NF-κB inhibit ‘classical’ macrophage activation through negative crosstalk with STAT-1 (Figure 3) [60,61].”
BackgroundInfluentialSelf-citationBahrami, A., Hassanian, S. M., Khazaei, M., Hasanzadeh, M., Shahidsales, S., Maftouh, M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26183 · Cited by 68
“Currently, major therapeutic strategies are focused only against active proliferating cells, but other tumor related cells such as macrophages and quiescent neoplastic cells remain unaffected [Hagemann et al., 2008].”
BackgroundZhang, H., Dai, Y., Liu, Y., Wu, T., Li, J., Wang, X., & Wang, W. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy107 · Cited by 64
Andersen, M. N., Etzerodt, A., Graversen, J. H., Holthof, L. C., Moestrup, S. K., Hokland, M., & Møller, H. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02301-3 · Cited by 67
3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy
Zhu, Y., Kang, E., Wilson, M., Basso, T., Chen, E., Yu, Y., & Li, Y.-R. (2022) · Organoids · doi:10.3390/organoids1020012 · Cited by 67
“Previous studies have shown that nuclear factor κB (NF-κB) signaling pathway can be specifically inhibited to restore TAM cytotoxicity, and that hypoxia-inducible factor-1α (HIF-1α) deletion in macrophages can reduce tumor growth [15,16].”
BackgroundMacrophage colony-stimulating factor and cancer: a review
Chockalingam, S., & Ghosh, S. S. (2014) · Tumor Biology · doi:10.1007/s13277-014-2627-0 · Cited by 67
Liao, D., Liu, Z., Wrasidlo, W., Luo, Y., Nguyen, G., Chen, T., Xiang, R., & Reisfeld, R. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1264 · Cited by 67
Panahi, Y., Darvishi, B., Ghanei, M., Jowzi, N., Beiraghdar, F., & Varnamkhasti, B. S. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.12.004 · Cited by 65
Jackaman, C., Yeoh, T. L., Acuil, M. L., Gardner, J. K., & Nelson, D. J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1173299 · Cited by 75
Therapeutic potential of the vagus nerve in cancer
Reijmen, E., Vannucci, L. E., Couck, M., Grève, J. D., & Gidron, Y. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.07.006 · Cited by 64
Ayala, T. S., Tessaro, F. H. G., Jannuzzi, G. P., Bella, L. M., Ferreira, K. S., & Martins, J. O. (2019) · Scientific Reports · doi:10.1038/s41598-019-47836-8 · Cited by 69
Exercise, Physical Activity and Breast Cancer: The Role of Tumor-Associated Macrophages
Goh, J., Kirk, E. A., Lee, S. X., & Ladiges, W. (2026) · PubMed · doi:10.22029/eir.2012.1673 · Cited by 62
Anti-Helicobacter pylori Potential of Artemisinin and Its Derivatives
Goswami, S., Bhakuni, R. S., Chinniah, A., Pal, A., Kar, S. K., & Das, P. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00407-12 · Cited by 64
Tumor-associated macrophages in thoracic malignancies
Lievense, L. A., Bezemer, K., Aerts, J. G. J. V., & Hegmans, J. P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.017 · Cited by 65
Spear, P., Barber, A., & Sentman, C. L. (2013) · OncoImmunology · doi:10.4161/onci.23564 · Cited by 61
IKK/Nuclear Factor-kappaB and Oncogenesis
Bradford, J. W., & Baldwin, A. S. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00003-2 · Cited by 62
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization
Yang, M. H., Shao, J.-H., Miao, Y.-J., Cui, W., Qi, Y.-F., Jh, H., Lin, X., & Du, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.45 · Cited by 60
“These results are consistent with the finding that NF-kB activation would support an anti-inflammatory, immunosuppressive M2 phenotype in a mouse model of ovarian cancer as suggested by Hagemann et al.33 CARD9 was recently shown to be a key integrator of immune responses, which leads to downstream formation of a signa…”
BackgroundMethodGhosh, S., Mukherjee, S., Choudhury, S., Gupta, P., Adhikary, A., Baral, R., & Chattopadhyay, S. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.03.013 · Cited by 63
“have reported that TAMs from NF-κB activationknockout mouse show M1 phenotype [49].”
BackgroundConnelly, L., Barham, W., Onishko, H. M., Chen, L., Sherrill, T. P., Zabuawala, T., Ostrowski, M. C., Blackwell, T. S., & Yull, F. E. (2011) · Breast Cancer Research · doi:10.1186/bcr2935 · Cited by 60
“Our data are in contrast with other in vivo studies highlighting a tumor-promoting role for macrophages [17,21].”
BackgroundResultCampisano, S., la Colla, A. B., Echarte, S. M., & Chisari, A. N. (2019) · Nutrition Research Reviews · doi:10.1017/s0954422418000239 · Cited by 69
“Contrariwise, adiponectin shifts KC polarisation to the M2 anti-inflammatory phenotype((93,94)), preventing NASH development((95)).”
BackgroundCD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion
Wang, F., Li, Y., Gao, Q., Huang, L. J., Wang, L., Wang, J., Wang, S., Zhang, B., & Zhang, Y. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1701-9 · Cited by 60
Pharmacological modulation of monocytes and macrophages
Mantovani, A., Vecchi, A., & Allavena, P. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.004 · Cited by 61
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu, J., Fu, L., Wu, R., Che, L., Liu, G., Ran, Q., Xia, Z., Liang, X., & Zhao, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517959 · Cited by 74
Yun, H.-M., Oh, J., Shim, J.-H., Ban, J. O., Park, K.-R., Kim, J.-H., Lee, D., Kang, J.-W., Park, Y. H., Yu, D., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.166 · Cited by 59
Ryan, A. E., Colleran, A., O'Gorman, A., O’Flynn, L., Pindjacova, J., Lohan, P., O’Malley, G., Nosov, M., Mureau, C., & Egan, L. J. (2014) · Oncogene · doi:10.1038/onc.2014.86 · Cited by 62
Lasithiotaki, I., Tsitoura, E., Samara, K. D., Trachalaki, A., Charalambous, I., Tzanakis, Ν., & Antoniou, K. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205242 · Cited by 59
Oral health and pathology: a macrophage account
Merry, R., Belfield, L., McArdle, P., McLennan, A., Crean, S., & Foey, A. (2011) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2010.10.020 · Cited by 59
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets
Szebeni, G. J., Vízler, C., Nagy, L. I., Kitajka, K., & Puskás, L. G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111958 · Cited by 62
“Inhibition of p50/p50 NF-κB nuclear translocation in TAMs [156], and the inhibition of IKKβ kinase reversed TAM phenotype from pro-tumoral to classically activated tumoricidal: IL-12high, MHCIIhigh, IL-10low, Arginase-1low [156,157].”
BackgroundLi, L., Han, L., Sun, F., Zhou, J., Ohaegbulam, K. C., Tang, X., Zang, X., Steinbrecher, K. A., Qu, Z., & Xiao, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1435250 · Cited by 54
Ghoneum, A., Afify, H. M. A., Salih, Z. T., Kelly, M., & Said, N. A. (2018) · Cancer Medicine · doi:10.1002/cam4.1741 · Cited by 61
Pathophysiologically relevant in vitro tumor models for drug screening
Das, V., Bruzzese, F., Konečný, P., Iannelli, F., Budillon, A., & Hajdúch, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.04.004 · Cited by 63
Gao, C.-H., Dong, H.-L., Tai, L., & Gao, X.-M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00037 · Cited by 57
“Currently, strategies to target M2 include depletion or blocking of recruitment (40, 41) and decreasing M2-like TAM via reeducation (42, 25).”
BackgroundWei, J., Dai, Y., Zhang, N., Wang, Z., Tian, X., Yan, T., Jin, X., & Jiang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408377 · Cited by 58
“It has been demonstrated that inhibiting IKK b in tumor-associated macrophages leads to increased expression of the antitumor cytokine IL-12 and inducible nitric oxide synthase, facilitating the transition of macrophage phenotype from M2 to M1 (143).”
BackgroundMacrophages, Neutrophils, and Cancer: A Double Edged Sword
Mantovani, A. (2014) · New Journal of Science · doi:10.1155/2014/271940 · Cited by 63
“Preclinical cancer models in the mouse indicate that it may be possible to “reeducate” tumor-promoting TAMs to reject neoplastic cells [141, 158].”
BackgroundStromal contributions to the carcinogenic process
Spaw, M., Anant, S., & Thomas, S. M. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22583 · Cited by 51
“Inhibition of IkK Kinase b, the major activator of NF-kb, led to re-education of TAM promoting direct tumoricidal activity through phagocytosis and NO production and indirectly through IL-12 production leading to NK cell mediated tumor death [58].”
BackgroundMacrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Stöger, J. L., Goossens, P., & de Winther, M. P. J. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110790886983 · Cited by 61
Peng, J., Tsang, J. Y. S., Li, D., Niu, N., Ho, D. H. H., Lau, K., Lui, V. C. H., Lamb, J. R., Chen, Y., & Tam, P. K. H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.001 · Cited by 54
“In animal studies, the depletion of TAMs by Clodronate encapsulated in liposomes (clodrolip) [8,33] or genetically modified IjB kinase b expression can reprogram the functional phenotype of TAMs [6,11] leading to reduced tumor progression and prolonged survival.”
BackgroundThe Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages
Movahedi, K., & Van Ginderachter, J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6704 · Cited by 53
“Remarkably, IL-1R signaling has also been shown to promote the M2 state and the pro-tumoral functions of TAMs, via an NF-j B-dependent pathway (61).”
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia
Hanna, B. S., Öztürk, S., & Seiffert, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.014 · Cited by 56
Ma, Y., He, X., Wang, H., Xia, Y., Wang, S., Ye, Z., & Tao, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01795.x · Cited by 55
Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth
Achyut, B. R., Angara, K., Jain, M., Borin, T. F., Rashid, M. H., Iskander, A., Ara, R., Kolhe, R. B., Howard, S., Venugopal, N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14079-4 · Cited by 52
Tellechea, M., Buxadé, M., Tejedor, S., Aramburu, J., & López-Rodríguez, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1601942 · Cited by 50
Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
Ye, P., Chi, X., Cha, J., Luo, S., Yang, G., Yan, X., & Yang, W. (2021) · Cells · doi:10.3390/cells10123309 · Cited by 54
Regulation of cancer stem cell activities by tumor-associated macrophages.
Jinushi, M., Baghdadi, M., Chiba, S., & Yoshiyama, H. (2012) · Europe PMC (PubMed Central) · Cited by 56
IKK- and NF-κB-Mediated Functions in Carcinogenesis
Arkan, M. C., & Greten, F. R. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_97 · Cited by 55
“Another function of NF-jB specifically found in tumor associated macrophages (TAM) was demonstrated by Fran Balkwill’s group using a model of metastasized ovarian cancer (Hagemann et al. 2008).”
BackgroundSmac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity
Lecis, D., De Cesare, M., Perego, P., Conti, A., Corna, E., Drago, C., Seneci, P., Walczak, H., Colombo, M. P., Delia, D., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.449 · Cited by 50
Shamsi, M. M., Chekachak, S., Soudi, S., Gharakhanlou, R., Quinn, L. S., Ranjbar, K., Rezaei, S., Shirazi, F. J., Allahmoradi, B., Yazdi, M. H., et al. (2018) · Nutrition · doi:10.1016/j.nut.2018.05.022 · Cited by 50
Zhang, T., & Sentman, C. L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201314 · Cited by 53
“shown that the NF-kB signaling pathway is important in cancerrelated inflammation and malignant progression (41, 42).”
BackgroundFuentes, L., Wouters, K., Hannou, S. A., Cudejko, C., Rigamonti, E., Mayi, T. H., Derudas, B., Pattou, F. N., Chinetti, G., Staels, B., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2324-0 · Cited by 51
“Alternatively, NFκB has been shown to maintain the M2 polarisation status in tumour-associated macrophages [30], suggesting that a decrease in NFκB signalling itself could also contribute to the decreased M2 profile of macrophages overexpressing p16.”
BackgroundWilson, A. J., Saskowski, J. L., Barham, W. J., Khabele, D., & Yull, F. E. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0463-5 · Cited by 48
“Ovarian tumors are known to polarize macrophages in the tumor microenvironment to display pro-tumorigenic characteristics via aberrant NF-κB signaling activity [17, 18].”
BackgroundWeigert, A., Mora, J., Sekar, D., Syed, S. N., & Brüne, B. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_9 · Cited by 51
“Pharmacological inhibition of NF-kB in TAMs also promoted regression of advanced tumors in vivo by induction of macrophage tumoricidal activity and activating antitumor activity through IL-12-dependent NK cell recruitment [ 93 ].”
BackgroundKhalife, J., Ghose, J., Martella, M., Viola, D., Rocci, A., Troadec, E., Terrazas, C. A., Satoskar, A. R., Gunes, E. G., Donà, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129348 · Cited by 50
“The importance of miR-16 in impairing M2-MΦ differentiation through IKKβ targeting is also supported by previously published data showing that the NF-κB canonical pathway alone is essential to maintain an M2 phenotype, as only the MΦ isolated from IKKβ-KO mice could be reeducated to have antitumor activity, in contras…”
ResultZhao, Y., Ge, X., Xu, X., Yu, S., Wang, J., & Sun, L. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03041-8 · Cited by 51
Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages
Martile, M. D., Farini, V., Consonni, F. M., Trisciuoglio, D., Desideri, M., Valentini, E., D’Aguanno, S., Tupone, M. G., Buglioni, S., Ercolani, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000489 · Cited by 52
Mola, S., Pandolfo, C., Sica, A., & Porta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186866 · Cited by 47
“The impact of myeloid-specific NF-κB activation on CRC development is more complex since the formation of different NF-κB dimers induces distinct macrophage activation states [66], which are associated with either tumor promotion or resistance [67,68].”
BackgroundIKKβ/NF-κB and the miscreant macrophage
Timmer, A. M., & Nizet, V. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081056 · Cited by 49
Zhao, G., Liu, L., Peek, R. M., Hao, X., Polk, D. B., Li, H., & Yan, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.750182 · Cited by 47
Ojalvo, L. S., Thompson, E. D., Wang, T., Meeker, A. K., Shih, I., Fader, A. N., Cimino‐Mathews, A., & Emens, L. A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.12.010 · Cited by 50
Naturally occurring compounds in differentiation based therapy of cancer
Mijatović, S., Bramanti, A., Nicoletti, F., Fagone, P., Kaluđerović, G. N., & Maksimović‐Ivanić, D. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.001 · Cited by 47
Pan, Y., Tan, Y., Wang, M., Zhang, J., Zhang, B., Yang, C., Ding, Z., Dong, L., & Wang, H. (2013) · Hepatology · doi:10.1002/hep.26391 · Cited by 46
“It is reported that IKKb could inhibit Stat1 activation in tumor-polarized Mw.21 We found that Stat1 activation was inhibited in SIRPa-KD Mw, which may partly be due to the increased functional form of IKKb.”
BackgroundInfluentialInflammation, Tumor Necrosis Factor and Wnt Promotion in Gastric Cancer Development
Oguma, K., Oshima, H., & Oshima, M. (2010) · Future Oncology · doi:10.2217/fon.10.13 · Cited by 48
Chen, E. P., Markosyan, N., Connolly, E., Lawson, J. A., Li, X., Grant, G. R., Großer, T., FitzGerald, G. A., & Smyth, E. M. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu053 · Cited by 48
“Supporting this concept, interference with NFκB signaling, which is established to induce COX-2 expression (44,45), in adoptively transferred BMDM or TAM led to suppressed M2-like phenotype with coincident reduction in tumor growth of an ovarian tumor cell line (46).”
BackgroundNiu, Y., Bai, J., Kamm, R. D., Wang, Y., & Wang, C. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500054h · Cited by 46
Wang, L., Liu, J., Talebian, F., El‐Omrani, H. Y., Khattabi, M., Li, Y., & Bai, X. (2010) · European Journal of Immunology · doi:10.1002/eji.201040472 · Cited by 48
“A recent study [43] has clearly shown that “re-educated” TAMC (devoid of IL-10 production) can efficiently kill cancer cells rather than promote tumor progression.”
BackgroundA novel moonlight function of glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) for immunomodulation
Nakano, T., Goto, S., Takaoka, Y., Tseng, H., Fujimura, T., Kawamoto, S., Ono, K., & Chen, C. (2017) · BioFactors · doi:10.1002/biof.1379 · Cited by 47
Ho, T., Chen, S., Shih, S., Chang, S., Yang, S.-L., Hsieh, J.-W., Cheng, H.-C., Chen, L.-J., & Tsao, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266064 · Cited by 44
Surdziel, E., Clay, I., Nigsch, F., Thiemeyer, A., Allard, C., Hoffman, G. R., Reece-Hoyes, J. S., Phadke, T., Gambert, R., Keller, C. G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183679 · Cited by 47
CK2 and the Hallmarks of Cancer
Firnau, M.-B., & Brieger, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081987 · Cited by 44
“demonstrated that NF-κB maintains the immunosuppressive phenotype of TAMs [564].”
BackgroundInfluentialJoimel, U., Gest, C., Soria, J., Pritchard, L.-L., Alexandre, J., Laurent, M., Blot, E., Cazin, L., Vannier, J.-P., Varin, R., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-375 · Cited by 43
“[20,21] and Greten et al.”
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines
Fox, B. A., Sanders, K. L., Chen, S., & Bzik, D. J. (2013) · Trends in Parasitology · doi:10.1016/j.pt.2013.07.001 · Cited by 44
Wang, C., Cui, A., Bukenya, M., Aung, A., Pradhan, D., Whittaker, C. A., Agarwal, Y., Thomas, A., Liang, S., Amlashi, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110021 · Cited by 48
Important Cells and Factors from Tumor Microenvironment Participated in Perineural Invasion
Chen, Z., Fang, Y., & Jiang, W. (2023) · Cancers · doi:10.3390/cancers15051360 · Cited by 46
Joshi, S., Liu, K. X., Zulcic, M., Singh, A. R., Skola, D., Glass, C. K., Sanders, P. D., Sharabi, A. B., Pham, T. V., Tamayo, P., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0947 · Cited by 50
Altered Phenotype of NK Cells From Obese Rats Can Be Normalized by Transfer Into Lean Animals
Lautenbach, A., Wrann, C. D., Jacobs, R., Müller, G., Brabant, G. E., & Nave, H. (2009) · Obesity · doi:10.1038/oby.2009.140 · Cited by 44
“The importance of the immunological microenvironment for immune functions has already been recognized, for example, the essentiality of a highly organized lymphoid architecture for effective cell–cell interactions in the lymph node (33) or the suppression of the local immune response by tumor cells (34).”
BackgroundPathogenetic role and clinical significance of interleukin‐1β in cancer
Malkova, A. M., Gubal, A. R., Petrova, A. L., Voronov, E., Apte, R. N., Semenov, K. N., & Sharoyko, V. V. (2022) · Immunology · doi:10.1111/imm.13486 · Cited by 47
“This process was experimentally shown in murine models of melanoma, breast cancer, fibrosarcoma and neck and head cancers [23,49,54].”
Background
Metadata
- Authors
- Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R.
- Affiliations
- Queen Mary University of London (GB)
- 1Centre for Cancer and Inflammation
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-05-19
- Volume
- 205
- Issue
- 6
- Pages
- 1261-1268
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2413024
- OpenAlex
- W2105724560
- Cited by
- 792
- References
- 25
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 32 · 2023: 28 · 2022: 42 · 2021: 41 · 2020: 45 · 2019: 31 · 2018: 50 · 2017: 49 · 2016: 49 · 2015: 46 · 2014: 73 · 2013: 64 · 2012: 41
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- tumor-associated macrophages, NF-κB signaling, macrophage polarization, alternative macrophage activation, IκB kinase β, MyD88, interleukin-1 receptor, IL-12, NK cell recruitment, tumor immunosuppression, tumor microenvironment, antitumor immunity, tumor regression
- MeSH terms
- Animals, Cell Differentiation, Humans, Immunosuppression Therapy, Macrophages, Neoplasms, Phenotype, Signal Transduction, NF-kappa B, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.